Summary: Centessa Pharmaceuticals has made progress in its orexin receptor 2 agonist program, focusing on the development of treatments for sleep-wake disorders such as narcolepsy and idiopathic hypersomnia. The company has initiated a phase 1 clinical trial for ORX750, with … [Read more...]
Orexin System-Based Drugs for Narcolepsy Are Coming
By Sree Roy Narcolepsy pharmacotherapies have existed in the US prescription drug market for decades. However none have targeted the orexin (hypocretin) system, even though it lies at the root of the neurological sleep disorder. But several biopharmaceutical companies are … [Read more...]
NLS Pharmaceutics Secures Patent for Dual Orexin Receptor Agonists
Summary: NLS Pharmaceutics Ltd announced the publication of a new patent application by Aexon Labs with the World Intellectual Property Organization, introducing a novel series of dual orexin receptor agonists. These compounds are designed to treat narcolepsy and … [Read more...]
NLS Secures Exclusive License for Dual Orexin Agonist Platform
Swiss biopharmaceutical enterprise NLS Pharmaceutics Ltd declared an exclusive worldwide license arrangement with Aexon Labs Inc, a US-centered biotech agency, to purchase global advancement and commercialization legal rights to Aexon’s twin orexin receptor agonists system. These … [Read more...]